Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Peramivir conjugates as orally available agents against influenza H275Y mutant.

European journal of medicinal chemistry - 10 Feb 2018

Wang Peng-Cheng, Chiu Din-Chi, Jan Jia-Tsrong, Huang Wen-I, Tseng Yin-Chen, Li Ting-Ting, Cheng Ting-Jen, Tsai Keng-Chang, Fang Jim-Min

Abstract excerpt

Peramivir is an efficacious neuraminidase (NA) inhibitor for treatment of influenza by intravenous administration. However, the efficacy of peramivir toward the H275Y mutant is appreciably reduced. To address this drawback, conjugation of peramivir with caffeic acid is devised in this study to enhance the binding affinity with neuraminidases. The C2-OH group of peramivir is elaborated to link with caffeate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Cyclopentanes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Guanidines

Share to Influenza A virus

Share to Molecular Structure

Share to Rabbits

Share to Structure-Activity Relationship

Source

Identifiers

PMID: 29324342
DOI: 10.1016/j.ejmech.2017.12.072

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Peramivir conjugates as orally available agents against influenza H275Y mutant.PMID 29324342Read ↗

Peramivir analogues bearing hydrophilic side chains exhibit higher activities against H275Y mutant than wild-type influenza virus.Semantic proximity Read ↗

The current strategies of optimization of oseltamivir against mutant neuraminidases of influenza A：A review.Semantic proximity Read ↗

Discovery of acylguanidine oseltamivir carboxylate derivatives as potent neuraminidase inhibitors.Semantic proximity Read ↗

Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.Semantic proximity Read ↗

Identification of neuraminidase inhibitors against dual H274Y/I222R mutant strains.Semantic proximity Read ↗

Influenza neuraminidase: A druggable target for natural productsSemantic proximity Read ↗

Peramivir binding affinity with influenza A neuraminidase and research on its mutations using an induced-fit docking approach.Semantic proximity Read ↗

Zanamivir-Cholesterol Conjugate: A Long-Acting Neuraminidase Inhibitor with Potent Efficacy against Drug-Resistant Influenza Viruses.Semantic proximity Read ↗

Novel binding patterns between ganoderic acids and neuraminidase: Insights from docking, molecular dynamics and MM/PBSA studies.Semantic proximity Read ↗

In Silico Studies Reveal Peramivir and Zanamivir as an Optimal Drug Treatment Even If H7N9 Avian Type Influenza Virus Acquires Further Resistance.Semantic proximity Read ↗

Structural analysis of the novel influenza A (H7N9) viral Neuraminidase interactions with current approved neuraminidase inhibitors Oseltamivir, Zanamivir, and Peramivir in the presence of mutation R289K.Semantic proximity Read ↗

Discovery of hydrazide-containing oseltamivir analogues as potent inhibitors of influenza A neuraminidase.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.